[go: up one dir, main page]

ME02202B - Jedinjenja pirolopirimidina kao inhibitori cdk4/6 - Google Patents

Jedinjenja pirolopirimidina kao inhibitori cdk4/6

Info

Publication number
ME02202B
ME02202B MEP-2015-157A MEP15715A ME02202B ME 02202 B ME02202 B ME 02202B ME P15715 A MEP15715 A ME P15715A ME 02202 B ME02202 B ME 02202B
Authority
ME
Montenegro
Prior art keywords
pyridin
pyrrolo
ylamino
diaza
cyclopentyl
Prior art date
Application number
MEP-2015-157A
Other languages
English (en)
Inventor
Yaping Wang
Christopher Thomas Brain
Young Shin Cho
John William Giraldes
Bharat Lagu
Julian Levell
Michael LUZZIO
Lawrence Blas Perez
Fan Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ME02202B publication Critical patent/ME02202B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (25)

1. Jedinjenje prema formuli (I)naznačen time, što:R1 predstavlja C3-7alkil; C4-7 cikloalkil po slobodnom izboru supstituisan sa jednim ili više supstituenta koji su odabrani iz grupe koju čine C1-6alkil i OH; fenil po slobodnom izboru supstituisan jednim supstitutentom koji je odabran iz grupe koju čine C1-6 alkil, C(CH3)2CN, i OH; piperidinil po slobodnom izboru supstituisan sa jednom ciklopropil grupom ili C1-6 alkilom; tetrahidropiranil po slobodnom izboru supstituisan sa jednom ciklopropil grupom ili C1-6 alkilom; ili biciklo[2.2.1]heptanil;gde A predstavlja CH ili N;gde R11 predstavlja vodonik ili C1-4 alkil;gde L predstavlja vezu, C(O), ili S(O)2;gde R2Y može da bude izabran iz grupe koju čineV je NH ili CH2;X je O ili CH2;W je O ili NH;gde m i n svaki za sebe predstavljaju 1, 2, ili 3 pod uslovom da m i n nisu oba 3;gde je svaka R2Y po slobodnom izboru supstituisana sa jednim do četiri supstituenata od kojih je svaki nezavisno odabran iz grupe koju čine: C1-3 alkil po slobodnom izboru substituisan sa jednim ili dva supstituenta od kojih je svaki nezavisno odabran iz grupe koju čine hidroksi, NH2, i -S-C1-3alkil; CD3; halo; okso; C1-3 haloalkil; hidroksi; NH2; dimetilamino; benzil; -C(O)-C1-3alkil po slobodnom izboru supstituisan sa jednim ili dva supstituenta od kojih je svaki odabran iz grupe koju čine NH2’ -SCH3 i NHC(O)CH3; - S(O)2-C1-4 alkil; i pirolidinil-C(O)-;gde R4 predstavlja, vodonik, deuterijum, ili C(R5)(R6)(R7); igde R5, R6, R7, R8, R9 i R10 svaki za sebe nezavisno predstavljaju H ili deuterijum; ili njena farmaceutski prihvatljiva so.
2.Jedinjenje formule (I-B) prema patentnom zahtevu 1, naznačen time, što L predstavlja vezu ili C(O); gde R2Y može da bude izabran iz grupe koju čine V je NH ili CH2; X je O ili CH2; W je O ili NH; gde m i n svaki za sebe nezavisno mogu da budu 1, 2, ili 3 pod uslovom da m i n m i n nisu oba 3; gde je svaka R2Y po slobodnom izboru supstituisana sa jednim do četiri supstituenata od kojih je svaki odabran iz grupe koju čine: C1-3 alkil po slobodnom izboru substituisan sa jednim ili dva supstituenta od kojih je svaki nezavisno odabran iz grupe koju čine hidroksi, NH2, i -S-C1-3alkil; CD3; C1-3 haloalkil; hidroksi; NH2; dimetilamino; benzil; -C(O)-C1-3alkil po slobodnom izboru supstituisan sa jednim ili dva supstituenta od kojih je svaki odabran iz grupe koju čine NH2’ -SCH3 i NHC(O)CH3; - S(O)2-C1-4 alkil; i pirolidinil-C(O)-; ili njena farmaceutski prihvatljiva so.
3. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što A predstavlja CH i R11 je vodonik; ili njena farmaceutski prihvatljiva so.
4. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što R4 predstavlja C(R5)(R6)(R7) i R5, R6, R7, R8, R9 i R10 mogu da predstavljaju vodonik, ili njenu farmaceutski prihvatljivu so.
5. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što R1 predstavlja C4-7 cikloalkil koji je po slobodnom izboru supstituisan jednom C1-6 alkil grupom, ili njena farmaceutski prihvatljiva so.
6. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što je R2Y nesupstituisana ili njena farmaceutski prihvatljiva so.
7. Jedinjenje prema bilo kojem od patentnih zahteva 1-5 naznačen time, što R2Y predstavlja ili od kojih je bilo koja po slobodnom izboru supstituisana C1-3alkilom, ili njena farmaceutski prihvatljiva so.
8. Jedinjenje prema bilo kojem od patentnih zahteva 1-5 naznačen time, što R2Y predstavlja koja je po slobodnom izboru supstituisana C1-3 alkilom, ili njena farmaceutski prihvatljiva so.
9. Jedinjenje formule (I-C) u kojoj: R1 predstavlja ciklobutil, ciklopentil, cikloheksil, cikloheptil, gde je svaka od njih po slobodnom izboru supstituisana sa jednom metil,etil, ili OH; gde A predstavlja CH ili N; L može da predstavlja vezu, -C(O)-, ili S(O)2-; gde R2Y može da bude jedna iz grupe koju čine ili gde je svaka R2Y po slobodnom izboru supstituisana jednim ili dva supstituenta koji su nezavisno odabrani iz grupe koju čine halogen, metil, etil, ili okso; gde V predstavlja NH ili CH2; gde R4 predstavlja vodonik, deuterijum, ili C(R5)(R6)(R7); i R5, R6, R7, R8, R9 i R10 svaki za sebe nezavisno predstavljaju H ili deuterijum; ili njena ili njena farmaceutski prihvatljiva so.
10. Jedinjenje prema patentnom zahtevu 9, naznačen time, što A predstavlja CH; ili njena farmaceutski prihvatljiva so.
11. Jedinjenje prema patentnom zahtevu 10 naznačen time, što L predstavlja vezu ili -C(O)- i gde R4 predstavlja CH3; i R8, R9 i R10 mogu da budu H; ili njena farmaceutski prihvatljiva so.
12. Jedinjenje prema patentnom zahtevu 11 naznačen time, što R1 predstavlja ciklopentil; ili njena farmaceutski prihvatljiva so.
13. Jedinjenje prema patentnom zahtevu 1, naznačen time, što može biti odabrano iz grupe koju čine: 2-(5-(2,6-Diazaspiro[3.3]heptan-2-karbonil)piridin-2-ilamino)-7-ciklopentil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-(4-terc-Butil-fenil)-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Cikloheptil-2-[5-(2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-8-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 2-(5-(2,7-diazaspiro[3.5]nonan-7-karbonil)piridin-2-ilamino)-7-cikloheptil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-ciklopentil-2-[5-(8-metil-3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; metilamid 7-Ciklopentil-2-[5-((S,S)-2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-(3-terc-Butil-fenil)-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 2-(5-((1R,5S)-3-oksa-7,9-diazabiciklo[3.3.1]nonan-9-karbonil)piridin-2-ilamino)-7-ciklopentil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-[4-(Cijano-dimetil-metil)-fenil]-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-8-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1S,6R)-3,9-diaza-biciklo[4.2.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-3,9-diaza-biciklo[4.2.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,6-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(5’-okso-8-azaspiro[biciklo[3.2.1]oktan-3,3’-pirolidin]-1’-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-Ciklopentil-2[5-(1-okso-heksahidro-pirolo[1,2-a]pirazin-2-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,8-diazaspiro[4.5]dekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-Ciklopentil-2-[5-((1S,6R)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 2-[5-(4-Okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7-fenil-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; i 7-cikloheksil-N,N-dimetil-2-(5-(4-okso-3,9-diazabiciklo[4.2.1]nonan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; ili njena farmaceutski prihvatljiva so.
14. Jedinjenje prema patentnom zahtevu 1, naznačen time, što može biti odabrano iz grupe koju čine: dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((S,S)-2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((1S,5S)-3,6-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklobutil-2-[5-((1S,6R)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Cikloheksil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)- piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-6-metil-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-4-metil-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,9-diaza-biciklo[3.3.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(3-okso-1,4-diazabiciklo[3.2.2]nonan-4-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((1R,6S)-9-metil-4-okso-3,9-diazabiciklo[4.2.1]nonan -3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aS,6aR)-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aR,6aS)-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-cikloheptil-N,N-dimetil-2-(5-(cis-6-oksotetrahidro-1H-pirolo[3,4-c]piridin-5(6H,7H,7aH)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(cis-6-oksotetrahidro-1H-pirolo[3,4-c]piridin-5(6H,7H,7aH)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aR,6aS)-5-metil-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((1R,3r,5S)-2’-okso-8-azaspiro[biciklo[3.2.1]oktan-3,5’-oksazolidin]-3’-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,8-diazaspiro[4.6]undekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,7-diazaspiro[4.5]dekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamide; dimetilamid 7-Ciklopentil-2-[5-((S)-2-okso-1-oksa-3,7-diaza-spiro[4.5]dec-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; i dimetilamid 7-Ciklopentil-2-[5-((R)-2-okso-1-oksa-3,7-diaza-spiro[4.5]dec-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; ili njena farmaceutski prihvatljiva so.
15. Jedinjenje prema patentnom zahtevu 1, naznačen time, što 7-ciklopentil-N,N-dimetil-2-(5-((1R,6S)-9-metil-4-okso-3,9-diazabiciklo[4.2.1]nonan-3-il)piridin-2-ilamino)-7H-pirolo[2,32,3-d]pirimidin-6-karboksamid ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
16. Jedinjenje prema patentnom zahtevu 1, naznačen time, što dimetilamid 7-Ciklopentil-2-[5-(3,8-diazabiciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
17. Jedinjenje prema patentnom zahtevu 1, naznačen time, što dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu ili njena farmaceutski prihvatljiva so.
18. Jedinjenje prema patentnom zahtevu 1, naznačen time, što metilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
19. Jedinjenje prema patentnom zahtevu 1, naznačen time, što metilamid 7-ciklopentil-2-[5-((1R,6S)-9-metil-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
20. Farmaceutska kompozicija koja obuhvata jedinjenje prema bilo kojem od predhodnih patentnih zahteva, ili njena farmaceutski prihvatljiva so, i farmaceutski prihvatljivi nosač ili ekscipijent.
21. Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u medicini.
22. .Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u lečenju raka.
23. Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u lečenju raka, naznačen time, što je odabrano iz grupe koju čine: mantle ćelijski limfom, multipli mijelom, rak dojke, ezofagealni kancer skvamoznih ćelija, liposarkom, T-ćelijski limfom, melanom, nesitnoćelijski rak pluća i rak pankreasa, folikularni karcinom štitaste žlezde, tumor mezenhimalnog porekla, fibrosarkom, rabdomiosarkom, tumor centralnog ili perifernog nervnog sistema, astrocitom, neuroblastom, gliom, švanom, melanom, seminom, teratokarcinom, osteosarkom, kseroderma pigmentozum, retinoblastom, keratoakatantom, i Kapošijev sarkom, karcinom bešike, dojke, debelog creva, bubrega, epidermis, jetre, pluća, ezofagusa (jednjaka), žučne kese, karcinom jajnika, pankreasa, stomaka, cerviksa, štitne žlezde, nosa, glave i jezika, prostate, i kože, leukemija, akutna limfocitna leukaemija, hronična limfocitna leukaemija, B-ćelijski limfom, difuzni krupnoćelijski B limfom, T-ćelijski limfom, Hodžkinov limfom, ne Hodžkinov limfom, limfom vlasastih ćelija, i Burkitov limfom, glioblastom multiforme, T ćelijski ALL, sarkomi i familijarni melanom.
24. Upotreba jedinjenja prema patentnom zahtevu 1 u proizvodnji leka za lečenje raka.
25. Jedinjenje formule (I) prema patentnom zahtevu 1, ili njena farmaceutski prihvatljiva so u kombinaciji sa jednim ili više drugih terapijskih sredstava za simultanu, odvojenu ili sekvencijalnu upotrebu u terapiji. EP 2 536 730 B1 REFERENCE KOJE SU NAVEDENE U OPISU Popis literature od strane podnosioca služi samo kao priručnik za čitaoca. Priručnik nije deo Evropske patent dokumentacije. Iako se posvećuje velika pažnja prevodu referenci, greške i propusti ne mogu biti izuzeti i EPO se odriče svake odgovornosti u tom smislu • WO 2007140222 A [0006] • WO 2009085185 A [0006] • WO 2008135232 A [0006] • US 20090203688 A [0006] • WO 2010020675 A [0134] [0267] [0274] • WO 2009067108 W [0260] • WO 2005097791 W [0279] • WO 2007040282 A [0303] • WO 2006137769 W [0362] • DE 102005030051 A1 [0638] [0650] [0670] Nepatentna literatura koja je navedena u opisu: • ORTEGA et al. Biochimica et Biophysica Acta-Reviews on Cancer, 2002, vol. 1602 (1), 73-87 [0002] [0003] [0004] • SHAPIRO. Journal of Clinical Oncology, 2006, vol. 24 (11), 1770-1783 [0002] [0003] • LUNDBERG et al. Molecular and Cellular Biology, 1998, vol. 18 (2), 753-761 [0002] • KAMB et al. Science, 1994, vol. 264 (5157), 436-440 [0002] [0004] • SHERR et al. Genes & Development, vol. 13 (12), 1501-1512 [0002] • AMIN et al. Archives of Pathology & Laboratory Medicine, 2003, vol. 127 (4), 424-431 [0003] • OUDAT et al. Modern Pathology, 2001, vol. 14 (1), 175A [0003] • BERGSAGEL et al. Immunological Reviews, 2003, vol. 194 (1), 96-104 [0003] • JIANG et al. Cancer Research, 1992, vol. 52 (10), 2980-2983 [0004] • AMOLD et al. Journal of Clinical Oncology, 2005 [0004] • SIRVENT et al. American Journal of Surgical Pathology, 2007, vol. 31 (10), 1476-1489 [0004] • BRAMBILLA et al. Journal of Pathology, 1999, vol. 188 (4), 351-360 [0004] • COWGILL et al. American Journal of Surgery, 2003, vol. 186 (3), 279-286 [0004] • GAZZERI et al. Oncogene, 1998, vol. 16 (4), 497-504 [0004] • DAILEY et al. Cytokine & Growth Factor Reviews, 2005, vol. 16 (2), 233-247 [0005] • ENGELMAN. Nature Reviews Cancer, 2009, vol. 9 (8), 550-562 [0005] • GARCIA-ECHEVERRIA. Purinergic Signalling, 2009, vol. 5 (1), 117-125 [0005] • GRAY-SCHOPFER et al. Cancer and Metastesis Reviews, 2005, vol. 24 (1), 165-183 [0005] • JOHN et al. Oncogene, 2009, vol. 28, S14-S23 [0005] • SHARMA et al. Nature Reviews Cancer, 2007, vol. 7 (3), 169-181 [0005] • MORIARTY K.J. et al. Bioorg Med Chem Lett, 2006, vol. 16, 5778-5783 [0006] • Remington’s Pharmaceutical Sciences. Mack Publishing Company, 1985 [0053] • STAHL; WERMUTH. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Wiley-VCH, 2002 [0053] • GREEN ; WUTTS. Protective Groups in Organic Synthesis [0114] • AMIN, H. M. ; MCDONNELL, T. J. ; MEDEIROS, L. J. ; RASSIDAKIS, G. Z. ; LEVENTAKI, V.; ; O’CONNOR, S. L. ; KEATING, M. J. ; LAI, R. Characterization of 4 mantle cell lymphoma cell lines – Establishment of an in vitro study model. Arch. Pathol. Lab. Med., 2003, vol. 127, 424-431 [0886]
MEP-2015-157A 2010-02-19 2011-02-17 Jedinjenja pirolopirimidina kao inhibitori cdk4/6 ME02202B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30624810P 2010-02-19 2010-02-19
US201161429372P 2011-01-03 2011-01-03
US201161429997P 2011-01-05 2011-01-05
EP11707115.9A EP2536730B1 (en) 2010-02-19 2011-02-17 Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PCT/EP2011/052353 WO2011101409A1 (en) 2010-02-19 2011-02-17 Pyrrolopyrimidine compounds as inhibitors of cdk4/6

Publications (1)

Publication Number Publication Date
ME02202B true ME02202B (me) 2016-02-20

Family

ID=44201966

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-157A ME02202B (me) 2010-02-19 2011-02-17 Jedinjenja pirolopirimidina kao inhibitori cdk4/6

Country Status (38)

Country Link
US (2) US8957074B2 (me)
EP (1) EP2536730B1 (me)
JP (1) JP5788415B2 (me)
KR (1) KR101812357B1 (me)
CN (1) CN102918043B (me)
AR (1) AR080198A1 (me)
AU (1) AU2011217286B2 (me)
BR (1) BR112012020922B1 (me)
CA (1) CA2790637C (me)
CL (1) CL2012002270A1 (me)
DK (1) DK2536730T3 (me)
DO (1) DOP2012000225A (me)
EA (1) EA022355B1 (me)
EC (1) ECSP12012111A (me)
ES (1) ES2548532T3 (me)
GE (1) GEP20146146B (me)
HN (1) HN2012001744A (me)
HR (1) HRP20151071T1 (me)
IL (1) IL221520A (me)
MA (1) MA34066B1 (me)
ME (1) ME02202B (me)
MX (1) MX2012009613A (me)
NI (1) NI201200135A (me)
NZ (1) NZ601754A (me)
PE (1) PE20121815A1 (me)
PH (1) PH12012501649A1 (me)
PL (1) PL2536730T3 (me)
PT (1) PT2536730E (me)
RS (1) RS54263B1 (me)
SG (1) SG183218A1 (me)
SI (1) SI2536730T1 (me)
SM (1) SMT201500265B (me)
TN (1) TN2012000413A1 (me)
TW (1) TWI503322B (me)
UA (1) UA108369C2 (me)
UY (1) UY33227A (me)
WO (1) WO2011101409A1 (me)
ZA (1) ZA201206079B (me)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54876B1 (sr) 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SMT201800206T1 (it) 2008-07-08 2018-05-02 Incyte Holdings Corp 1,2,5-ossadiazoli come inibitori di indoleamina 2,3-diossigenasi
PE20110419A1 (es) 2008-08-22 2011-07-13 Novartis Ag Compuestos de pirrolo-pirimidina como inhibidores de cdk
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
JP5918214B2 (ja) * 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
BR112013033940A2 (pt) 2011-07-01 2017-02-14 Novartis Ag terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013148748A1 (en) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactam kinase inhibitors
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
PL2872491T3 (pl) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
EP4119676A1 (en) 2012-08-03 2023-01-18 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
PT3514158T (pt) 2013-01-29 2023-01-13 Aptinyx Inc Moduladores espirolactamas de um recetor nmda e as suas utilizações
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN108434149B (zh) 2013-03-15 2021-05-28 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
ES2900829T3 (es) * 2013-08-14 2022-03-18 Novartis Ag Terapia combinada para el tratamiento del cáncer
RU2704112C2 (ru) 2013-10-25 2019-10-24 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
CN110372720B (zh) * 2014-05-28 2021-03-05 锦州奥鸿药业有限责任公司 一类激酶抑制剂
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
KR102455043B1 (ko) * 2014-09-11 2022-10-13 얀센 파마슈티카 엔.브이. 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
JP6726677B2 (ja) * 2015-03-11 2020-07-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. 抗がん剤としての置換２−ｈ−ピラゾール誘導体
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
EP3383390A4 (en) * 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
MX387648B (es) * 2016-05-07 2025-03-18 Fochon Pharmaceuticals Ltd Derivados de heteroarilo tieno[3,2-d]pirimidina-6-carboxamida de la fórmula (ii) que presentan actividad inhibitoria sobre cinasa cdk4/6.
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
AU2017306136B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
PE20190503A1 (es) * 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
ES2934846T3 (es) 2016-10-20 2023-02-27 Pfizer Inhibidores de CDK para tratamiento de PAH
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
IL267299B (en) 2016-12-16 2022-09-01 Cstone Pharmaceuticals Cdk4/6 inhibitor
IL267795B2 (en) 2017-01-06 2023-02-01 G1 Therapeutics Inc Combination therapy for the treatment of cancer
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EA201992768A1 (ru) 2017-06-29 2020-05-19 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
CA3085366A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
BR112020013915A2 (pt) 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
BR112020015710A2 (pt) 2018-01-31 2020-12-08 Aptinyx Inc. Moduladores de espiro-lactamas de receptores nmda e usos dos mesmos
WO2019161224A1 (en) * 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
WO2019178239A1 (en) * 2018-03-13 2019-09-19 Board Of Regents, The University Of Texas System Methods for treatment of cancers with egfr activating mutations
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020077174A1 (en) * 2018-10-12 2020-04-16 Board Of Regents Of The University Of Nebraska Phosphodiesterase inhibitors
CN111100128B (zh) * 2018-10-26 2022-09-06 广安凯特制药有限公司 一种瑞博西尼中间产品的合成方法及其中间体化合物
US20230065740A1 (en) * 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
CA3130210A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
SG11202112229UA (en) 2019-05-05 2021-12-30 Qilu Regor Therapeutics Inc Cdk inhibitors
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022543062A (ja) 2019-08-01 2022-10-07 インサイト・コーポレイション Ｉｄｏ阻害剤の投与レジメン
CR20220066A (es) 2019-08-14 2022-11-28 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220087A1 (ar) 2019-10-11 2023-01-30 Incyte Corp أمينات ثنائية الحلقة كمثبطات لـ cdk2
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN121270549A (zh) 2020-04-16 2026-01-06 因赛特公司 稠合三环kras抑制剂
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
EP4153597B1 (en) 2020-05-19 2025-09-10 Pharmacosmos Holding A/S Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
TW202237585A (zh) 2020-11-27 2022-10-01 瑞士商瑞森製藥公司 Ｃｄｋ抑制劑
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL309642A (en) 2021-07-07 2024-02-01 Incyte Corp Tricyclic compounds as inhibitors of Kras
US20230114765A1 (en) 2021-07-14 2023-04-13 Incyte Corporation Tricyclic compounds as inhibitors of kras
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-｛[4-(디메틸아미노)피페리딘-1-일]카르보닐｝페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
CN117043163A (zh) * 2021-09-08 2023-11-10 希格生科（深圳）有限公司 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
EP4408536A1 (en) 2021-10-01 2024-08-07 Incyte Corporation Pyrazoloquinoline kras inhibitors
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras
US20230226040A1 (en) 2021-11-22 2023-07-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CA3244187A1 (en) 2021-12-22 2023-06-29 Incyte Corporation SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND THEIR METHODS OF PREPARATION
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
IL315457A (en) 2022-03-07 2024-11-01 Incyte Corp Solid forms, salts and preparation processes of the Sidikii2 inhibitor
EP4519267A1 (en) * 2022-05-05 2025-03-12 BeiGene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
EP4561991A1 (en) * 2022-07-25 2025-06-04 Cayman Chemical Company, Inc. Novel heterocycles as spla2-x inhibitors
CA3263134A1 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
TW202446371A (zh) 2023-04-18 2024-12-01 美商英塞特公司 ２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025096738A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
WO2025129002A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE60323946D1 (de) 2002-03-07 2008-11-20 Hoffmann La Roche Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CA2755297A1 (en) 2003-02-10 2004-08-26 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
AU2004270713A1 (en) 2003-09-05 2005-03-17 Aventis Pharmaceuticals Inc. Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
MXPA06002853A (es) 2003-09-11 2006-06-14 Kemia Inc Inhibidores citoquina.
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
AR049769A1 (es) * 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
WO2005080393A1 (en) 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007526906A (ja) 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
CN1964970B (zh) 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP2008506761A (ja) 2004-07-22 2008-03-06 アステックス、セラピューティックス、リミテッド プロテインキナーゼ阻害剤としてのチアゾールおよびイソチアゾール誘導体
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
JP5190271B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての５員の環付加複素環式ピリミジン
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
US20100160626A1 (en) 2005-06-20 2010-06-24 Astrazeneca Ab Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US20070225304A1 (en) 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
EP1932844B1 (en) 2005-10-06 2015-09-02 Nippon Soda Co., Ltd. Cross-linked cyclic amine compounds and agents for pest control
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
AU2006331765A1 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP2009529541A (ja) 2006-03-09 2009-08-20 ファーマコピア インコーポレーテッド 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
EP2024342A2 (en) 2006-05-01 2009-02-18 Pfizer Products Incorporated Substituted 2-amino-fused heterocyclic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
KR20100108341A (ko) 2007-11-20 2010-10-06 브리스톨-마이어스 스큅 컴퍼니 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제
NZ586069A (en) * 2007-12-19 2012-05-25 Amgen Inc Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
JP5323095B2 (ja) 2008-02-06 2013-10-23 ノバルティス アーゲー ピロロ［２，３−ｄ］ピリミジンおよびそのチロシンキナーゼ阻害剤としての使用
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
PE20110419A1 (es) 2008-08-22 2011-07-13 Novartis Ag Compuestos de pirrolo-pirimidina como inhibidores de cdk
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
JP5918214B2 (ja) 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos

Also Published As

Publication number Publication date
US20130150342A1 (en) 2013-06-13
EP2536730B1 (en) 2015-07-08
UY33227A (es) 2011-09-30
PH12012501649A1 (en) 2018-02-07
AU2011217286B2 (en) 2014-06-19
CN102918043A (zh) 2013-02-06
ECSP12012111A (es) 2012-09-28
EA201201161A1 (ru) 2013-03-29
DOP2012000225A (es) 2013-01-15
RS54263B1 (sr) 2016-02-29
AR080198A1 (es) 2012-03-21
EP2536730A1 (en) 2012-12-26
CA2790637C (en) 2018-04-10
BR112012020922A2 (pt) 2016-05-03
CN102918043B (zh) 2015-07-29
ES2548532T3 (es) 2015-10-19
US20150099737A1 (en) 2015-04-09
US8957074B2 (en) 2015-02-17
IL221520A (en) 2015-07-30
ZA201206079B (en) 2013-05-29
NI201200135A (es) 2012-10-30
TW201130848A (en) 2011-09-16
WO2011101409A1 (en) 2011-08-25
TN2012000413A1 (en) 2014-01-30
PT2536730E (pt) 2015-10-29
NZ601754A (en) 2014-04-30
MA34066B1 (fr) 2013-03-05
PL2536730T3 (pl) 2015-12-31
SI2536730T1 (sl) 2015-10-30
HK1176616A1 (en) 2013-08-02
HRP20151071T1 (hr) 2015-11-06
HN2012001744A (es) 2015-08-24
KR101812357B1 (ko) 2017-12-26
JP2013519707A (ja) 2013-05-30
CL2012002270A1 (es) 2012-10-26
TWI503322B (zh) 2015-10-11
CA2790637A1 (en) 2011-08-25
KR20130006625A (ko) 2013-01-17
PE20121815A1 (es) 2013-02-03
UA108369C2 (uk) 2015-04-27
MX2012009613A (es) 2012-09-12
EA022355B1 (ru) 2015-12-30
BR112012020922B1 (pt) 2020-12-22
AU2011217286A1 (en) 2012-08-30
SMT201500265B (it) 2016-01-08
US9309252B2 (en) 2016-04-12
JP5788415B2 (ja) 2015-09-30
GEP20146146B (en) 2014-08-25
DK2536730T3 (en) 2015-09-28
SG183218A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
ME02202B (me) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
JP2013519707A5 (me)
JP6263269B2 (ja) キナーゼ阻害剤及びその使用
AU2015296322B2 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
ES2531465T3 (es) Derivados de pirimidinona, su preparación y su utilización farmacéutica
AU2012339499B2 (en) Aminoquinazoline derivatives and their salts and methods of use
ME02635B (me) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
BR112020022201A2 (pt) análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor
JP2017222709A5 (me)
JP2015511245A5 (me)
JP2019535664A5 (me)
JP2013500975A5 (me)
NZ610018A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2014008913A (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
JP2015508075A5 (me)
JP2012528828A5 (me)
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
RU2009123930A (ru) Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4
JP2020527174A5 (me)
ME02922B (me) Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže
US12006320B2 (en) Heterocyclic derivatives as PI3K inhibitors
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
CN112867715A (zh) 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物
RU2023134860A (ru) Ингибиторы мутации her2
NZ772799A (en) Heterobicyclic compounds for inhibiting the activity of shp2